X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs PIRAMAL ENTERPRISES - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS PIRAMAL ENTERPRISES IPCA LABS/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 27.5 36.6 75.3% View Chart
P/BV x 2.1 3.6 57.9% View Chart
Dividend Yield % 0.2 0.7 36.5%  

Financials

 IPCA LABS   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    IPCA LABS
Mar-17
PIRAMAL ENTERPRISES
Mar-16
IPCA LABS/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs6431,065 60.4%   
Low Rs503805 62.5%   
Sales per share (Unadj.) Rs254.4383.0 66.4%  
Earnings per share (Unadj.) Rs16.155.1 29.2%  
Cash flow per share (Unadj.) Rs29.874.1 40.2%  
Dividends per share (Unadj.) Rs1.0017.50 5.7%  
Dividend yield (eoy) %0.21.9 9.3%  
Book value per share (Unadj.) Rs194.6719.9 27.0%  
Shares outstanding (eoy) m126.20172.56 73.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.32.4 92.3%   
Avg P/E ratio x35.717.0 210.0%  
P/CF ratio (eoy) x19.212.6 152.4%  
Price / Book Value ratio x2.91.3 226.7%  
Dividend payout %6.231.8 19.6%   
Avg Mkt Cap Rs m72,300161,344 44.8%   
No. of employees `00013.33.8 351.7%   
Total wages/salary Rs m6,96016,898 41.2%   
Avg. sales/employee Rs Th2,413.517,472.6 13.8%   
Avg. wages/employee Rs Th523.24,466.9 11.7%   
Avg. net profit/employee Rs Th152.42,512.8 6.1%   
INCOME DATA
Net Sales Rs m32,10666,099 48.6%  
Other income Rs m2262,425 9.3%   
Total revenues Rs m32,33268,524 47.2%   
Gross profit Rs m4,44818,723 23.8%  
Depreciation Rs m1,7303,274 52.8%   
Interest Rs m2419,388 2.6%   
Profit before tax Rs m2,7038,485 31.9%   
Minority Interest Rs m03 0.0%   
Prior Period Items Rs m01,593 0.0%   
Extraordinary Inc (Exp) Rs m0457 0.0%   
Tax Rs m6751,032 65.4%   
Profit after tax Rs m2,0289,506 21.3%  
Gross profit margin %13.928.3 48.9%  
Effective tax rate %25.012.2 205.4%   
Net profit margin %6.314.4 43.9%  
BALANCE SHEET DATA
Current assets Rs m17,34047,488 36.5%   
Current liabilities Rs m9,559104,362 9.2%   
Net working cap to sales %24.2-86.0 -28.2%  
Current ratio x1.80.5 398.6%  
Inventory Days Days10041 247.0%  
Debtors Days Days5751 111.2%  
Net fixed assets Rs m20,77926,532 78.3%   
Share capital Rs m252345 73.1%   
"Free" reserves Rs m24,499114,024 21.5%   
Net worth Rs m24,553124,221 19.8%   
Long term debt Rs m3,51775,812 4.6%   
Total assets Rs m39,595308,356 12.8%  
Interest coverage x12.21.9 642.2%   
Debt to equity ratio x0.10.6 23.5%  
Sales to assets ratio x0.80.2 378.3%   
Return on assets %5.76.1 93.5%  
Return on equity %8.37.7 107.9%  
Return on capital %10.510.0 105.3%  
Exports to sales %48.617.2 283.0%   
Imports to sales %14.26.6 215.6%   
Exports (fob) Rs m15,61711,362 137.5%   
Imports (cif) Rs m4,5714,364 104.7%   
Fx inflow Rs m15,61714,435 108.2%   
Fx outflow Rs m5,8285,183 112.4%   
Net fx Rs m9,7909,253 105.8%   
CASH FLOW
From Operations Rs m2,764-67,773 -4.1%  
From Investments Rs m-1,432-8,768 16.3%  
From Financial Activity Rs m-1,59176,199 -2.1%  
Net Cashflow Rs m-259-342 75.6%  

Share Holding

Indian Promoters % 45.9 52.9 86.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 4.0 285.0%  
FIIs % 25.3 26.6 95.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 16.5 105.5%  
Shareholders   36,892 93,274 39.6%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALEMBIC PHARMA  AJANTA PHARMA  

Compare IPCA LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Aug 23, 2017 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - ALEMBIC LTD COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS